In response to HSP90 inhibition, the co‐chaperone CDC37 dissociates from RPAP2 and promotes the rapid degradation of RPAP2 via CRL5FBXW7, thereby enhancing the sensitivity of cancer cells to HSP90 inhibitors. The gene discussed is RPAP2; the disease is cancer.